MedicaidPrior AuthMedium impact
Imjudo (tremelimumab-actl) (New)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
Dec 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Indiana has introduced a new prior authorization policy for Imjudo (tremelimumab-actl), an oncology drug used to treat hepatocellular carcinoma and non-small cell lung cancer. Prior authorization is required for all uses, with specific criteria including combination therapy requirements and genomic testing results for lung cancer patients.
Action Required
Before December 1, 2025: Billing team must implement prior authorization requirements for Imjudo (tremelimumab-actl) for Indiana Medicaid patients. Update billing software to flag this drug for prior auth. Providers treating hepatocellular carcinoma or non-small cell lung cancer patients must obtain prior authorization before administering Imjudo, ensuring combination therapy criteria are met. Visit www.humana.com/PAL for specific medical and procedural coding information. Claims will be denied without proper prior authorization.